Infinity Pharmaceuticals price target raised to $55 from $38 at RBC Capital RBC Capital expects Infiinity's stock to be pushed higher by favorable data at ASCO/ASH. The firm thinks the stock's valuation is attractive, and it maintains an Outperform rating on the shares.
Infinity Pharma lowers FY15 revenue view to $100M-$120M from $105M-$190M Consensus is for FY15 revenue $130.6M. Due to changes in the anticipated timing of the initiation of planned clinical studies as well as slower than expected enrollment in DYNAMO+R, Infinity provided the following updated financial guidance for 2015: revenue: Infinity sees FY15 revenue $100M-$120M, compared to prior expectations of $105M-$125M. Sees FY15 net Loss $125M-$145M, compared to prior expectations of $190M-$210M. Sees FY15 cash and Investments balance $230M-$250M, compared to prior expectations of $145M-$165M. This year-end cash and investments includes the $130M milestone payment from AbbVie associated with the completion of patient enrollment in DYNAMO.